🟢 Biovie is trading 6.14% up in pre-market after ending treatment in Phase 2 ADDRESS-LC trial

Biovie is trading 6.14% up at $2.42 after announcing on August 31, 2026, that treatment ended in its approximately 200-patient Phase 2 ADDRESS-LC trial of bezisterim for Long COVID neurological symptoms.

• Topline results are expected before September 30, 2026.
• Recent open-market purchases by the CEO, CFO, CMO, and a director strengthened investor sentiment despite weaker broader-market futures.